Accès ouvert
2026
conference-abstract
OpenAlex
Chiara Molinelli, Bárbara Cardinali, Benedetta Conte, Marco Bruzzone et autres
e12590 Background: Estrogen Receptor–Positive (ER+)/HER2-Negative early breast cancer (BC) is biologically heterogeneous: while most patients experience a favourable prognosis, 15–30% still relapse despite standard adjuvant therapy. As therapeutic options expand, reliable biomarkers are needed to guide escalation and de-escalation strategies. Genomic signatures …
it
(code pays fourni par la source)
2026
conference-abstract
OpenAlex
Bárbara Cardinali, Alice Stella, Chiara Molinelli, Marco Bruzzone et autres
Abstract Background: Approximately 47-65% of estrogen receptor-positive (ER+)/HER2-negative breast cancers (BC), although classified as HER2-negative due to the absence of HER2 gene amplification, exhibit low levels of HER2 expression (referred to as HER2-low BC) with immunohistochemistry (IHC) 1+ or 2+ without amplification …
it
(code pays fourni par la source)
2024
article
OpenAlex
Giovanni Musso, Silvia Pinach, Filippo Mariano, Francesca Saba et autres
BACKGROUND AND AIMS: NASH confers an increased liver-related and kidney morbidity. Phospholipid curcumin (Meriva) is a phospholipid formulation with ameliorated systemic curcumin absorption and delivery. We assessed the safety and efficacy of Meriva in NASH. APPROACH AND RESULTS: In this double-blind trial, …
it
(code pays fourni par la source)